冠心病用药准则研究进展
摘要
冠心病患者症状轻重与冠状动脉狭窄轻重不呈正相关。有些轻度～ 50％病变软斑突然破裂足 以发生严重急性心肌梗死远比冠状动脉严重狭窄发生急性心肌梗死多，研究表眀与软斑块炎症反应生物学特征 密切相关，不取决于冠状动脉严重程度。经 33 年循征医学研究证据表明阿托伐他汀能稳定斑块，逆转斑块， 4h 快速修复内皮细胞，增加纤维幅弹性与厚度，抑制炎症因子，显著降低心脑血管病发生率与死亡率。PCSk9 抑制剂问世对降脂与保护心脑血管病的患者带来福音，支架术适用于冠状动脉狭窄＞ 80％伴严重心绞痛或急性 心肌梗死並存或软斑块突然破裂致急性心肌梗死患者救急办法。微血管病变与与慢血流现象即血流灌注明显延 迟的无复流现象，尼可地尔可改善 PC1 无法解决的而却可显著减少慢血流现象发生，促使血流灌注充盈再通畅 可以防止心肌细胞凋亡、坏死，改善支架无法解决改善心肌缺血、凋亡与坏死通畅血流灌注量而改善心肌供血， 显著扩张冠状动脉，改善微循环包括侧支循环建立及心功能長期预后，减少氧自由基，保护线粒体，维持心肌 能量平衡，保护心肌细胞。参考
[1] 徐大立，钱中良，陶以嘉，急性冠脉综合征研
究进展，心血管病学杂志 (J),2006.17:36
[2] 徐大立，急性心肌梗死研究进展，心血管病学
杂志 (J),2005,26:89 ～ 93
[3]Davies.M.the.pot-hophysidy.of.acute.Conronay.
Syudromes.Heart.2009-9Ardastimi.E.M.ondini.P BeIlo.
Bp.et. al.New-insito.P-athohyastatin.Patent. with.stable.
coronary.desese(J)N.Eng-1.J.med.2005.382:425 ～ 435
[4] 徐大立、陶以嘉，急性冠脉综合征重建术 (J)，
2005.7:154~155
[5]Davies.M.the.pat-hophysidy.of.acute.Coronary.
syudromes.Heart.2000.83:361 ～ 366
[6]Ardastimi.E.BeIIo.at.el.New-insightis.inso.
P-athohysology.of.AM1.Heart.J.2013：138：6556 ～ 560
[7] 中华心血管病杂志编委会，经 PTCAT 介入治
疗指南 J，2009:347 ～ 425
[8] 陶以嘉、徐大立，ACS 与阿托伐他汀，心血
管病学进展 (J)2013,329(4):553-558.
[9]P1/ll 研究，2011 年 6 月第 47 屈歐洲透折和移
植 大 会 报 告 Nttp、/www.medscape. Com/Vrewar ti de
/724885.SATU1R 研 究 NichoI1s. Sl. Ballanontyre. C M.
Bartar.P.l.et.al. Esffect. of.two.in-tonsive.statin.regim ens
[10]GiugLiano RP,Cannon CP.Blazing MA,
etal.Benefit of adding ezetimibe to statin therapy
oncardiovascular outcomesandsafety in patients with
versus without diabetes mellitus:results from IMPROVE_xfffe_IT(erduction of outcomes:Vytprin efficacy international
trial)[J].circulation, 2018,137(15):1571-82
[11]Sabatine.MS.Giug1iano.RP.Keech.
A.et.al. EV0l0CDN1AB.and.c1inica1. outcome
in paticntis with cardiovascules disease(J).N.Engl.
J.Med.2017.376(18):1713 ～ 1722.Dor：10.1056/
NSJmo2161566Conna H,Ray kk. The importance of
dysLipidaemia in the pathogenesi of cardiovascuLar dise
ase in people wite diabetes[J].Diabetes Obes Metab,
2019.21(suppl 1):6-16
[12]Filippatos TD,Florentin M,Georgoula M,et al.
Pharmacological management of diabetic dyslipidemia [J].
Expert Rev Clin Pharmacol,2017,10(2):187-200
[13]George B,Lawrence B, Andrew JM,et al.Ame
rican Diabetes Association .Standards of Medical Care in
Diabetes -2020[J].Diabetes Care.2020.43(Suppl 1):Sl-S212
[14]Mach F,Baigent C,Catapano AL,et al.2019 ESC/
EAS Cuidelines for the management of dyslipidaemias :lipid
modification to reduce cardiovascular risk[ J] .European
heart journal,2020.41(1):111-88.
[15] 中 国 血 脂 管 理 指 南（2023 年）Chinese.Circ
utation.Jomnal.march.2023， Ⅴ ol.38.N0.3（Seria ｜ .
N0.297）....“17”Sabatine.MS，Giug1iano.RP.Keech.
A.C.et.al. EV0l0CDN1AB.and.c1inica1.outcome.
in.paticntis.with.cardiovascules.disease.(J).N.Engl.
J.Med.2017.376(18):1713 ～ 1722.Dor：10.1056/
NSJmo21615664......“22”O.DOnghue.ML.Giogliano.
RF.Wiviott.SD.et.al.Longterm.etherosclerotic.Pationts.
with.cstab1ished.atheosc.lerotic.Cardiovacutor.disase(J).
Circulation.2022.146(15);1109 ～ 1119.DOl.10.1161/
C1RC ∪ LATl0NAHA.122.0616.20
[16] 急性 STEM1 诊断与治疗指南 (J). 中华医学
会分会编辑委会，中华心血管病学杂志编委会，2020.
90:675~690
[17]Jennifer S. L , Jacqueline E. T H , Sripal B , et
al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery
Revascularization: A Report of the American College of
Cardiology/American Heart Association Joint Committee
on Clinical Practice Guidelines[J]. Circulation: An Official
Journal of the American Heart Association, 2022(145-3).
[18]Arbel R, Hammerman A,Azuri J.Usefulness
of ezetimibe versus evolocumab as addon therapy
for secondary prevention of cardiovascular events
in patients with type2 diabetes mellitus (J).Am
JCardiol,2019,123(8):1273-6
[19]Lorenzi M,Ambegaonkar B,Baxter CA,et
al.Ezetimibe in high-risk,previously treated statin
patients:a systematic review and network meta-analysis of
lipid efficacy(J).Clin Res Cardiol,2019,108(5):487-509.
[20]Sabatine MS,Ciugliano RP ,Keech AC,et
al.Evolocumab and clinical outcomes in patients with
cardiovascular diseaes[ J].N Engl J Med,2017.376(18):1713-
22.
[21]O.DOnghue.ML.Giogliano.RF.Wiviott.SID,et.
al.Longtermetherosclerotic.Pationts.with.cstab1ished.
atheosc.lerotic.Cardiovacutor.disase(J).Circulati
on.2022.146(15);1109～1119.DOl.10.1161/C1RC∪LAT
l0NAHA.122.0616.20Schwartz GG,Steg PG,Szarek M,et
al.Alirocumab and cardiovascular outcomes after acute
coronary syndrome [J].N Engl JMed,2018.379(22):2097-
107
[22]Monami M,Sesti G,M annucci E.PCSK9 inhibitor
therapy:asystematic review and meta-analysis of metabolic
and cardiovascular outcomes in patients with diabetes[J].
Diabetes Ohes Metab ,2019,21(4):903-8
[23]Kosmas GE,DeJesus E,Morcelo R,et al.Lipidlowering interventions targeting proprotein convertase
subtilisin/kexin type9(PCSK9)an emerging chapter in
lipid-lowering therapy[J].Drugs Context,2017,6:212511.
[24]Leiter LA,Teoh H,Kallend D,et al.Inclisiran
Lowers LDL-C and PCSK9 irrespective of diabetes
status:the ORION-1 randomized clinical trial[J].Diabetes
Care,2019,42(1):173-6
[25]Ray KK,Landmesser U,Leiter LA,et al.Inclisiran
in patients an high cardiovascular risk with elevated LDL
cholesterol[J].NEnglJMed,2017,376(15):1430-40
[26]Ray KK Wright RS,Kallend D,et al.Two
Phase3 Trials of Inclisisran in Patients with Elevaated LDL
Chonlesterol[J].Engl J Med,2020,382(16):507-19.
[27]1Keda.N.Yasu.T.kudo.N.et.al.Nicorandi1.
versus.isosorbide.dinitrate.as.adJunctive.treatment.to,direct.
balloon.angioplasty.in.acute.myocardial.infarctiion (J
).Heart.2004.90(20):181-185
[28] 黄静静，注射尼克地尔在 ACS 中应用进展，
心血管病学进展 .(J).2016.Vol.565-566
[29] 李佳、鄢华、苏晞 . 糖尿病血脂异常的药物
治疗新进展，中国循环心血管医学杂志（J) 2022.14（2）：
247-249
[30] 医学会心血管病学分会动脉粥样硬化与冠心
病学组，中华医学会心血管病学分会介入心脏病学组 ,
中国医师协会心血管内科医师分会血栓防治专业委员
会，等 . 冠心病双联抗血小板治疗中国专家共识 [J] 中
华心血管病杂 2021,49(5) : 432-454
[31] 葛均波 , 霍勇 , 杨杰孚 , 高秀芳 , 李勇 . 慢性
心力衰竭“新四联”药物治疗临床决策路径专家共识 [J].
中国循环杂志 ,2022,37(08):769-781.
[32] 医学会心血管病学分会动脉粥样硬化与冠心
病学组，中华医学会心血管病学分会介入心脏病学组，
中国医师协会心血管内科医师分会血栓防治专业委员
会，等 . 冠心病双联抗血小板治疗中国专家共识 [J] 中
华心血管病杂志 , 2021,49(5) : 432-454
[33] 葛均波 , 霍勇 , 杨杰孚 , 高秀芳 , 李勇 . 慢性
心力衰竭“新四联”药物治疗临床决策路径专家共识 [J].
中国循环杂志 ,2022,37(08):769-781.
